Results from a randomized phase III trial examining rituximab in patients with central nervous lymphoma show that treatment with rituximab does not improve response and survival rates – questioning the role of rituximab in this patient population.
Recent Articles
Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Relapsed/Refractory MM
Recent results suggest that in patients with relapsed multiple myeloma (MM), combination therapy consisting of carfilzomib and dexamethasone (Kd) plus isatuximab is associated with...
Ibrutinib Plus Venetoclax Shows Promise in Treatment-Naïve CLL
First-line combination therapy with ibrutinib and venetoclax was associated with higher rates of undetectable measurable residual disease (MRD), remission, and three-year progression-free survival (PFS)...
The Eye of a Survivor
While cure remains a goal, unique issues arise when treating professional and amateur athletes for hematologic conditions.
Athletic competition on an elite level depends on...
August 2021 Volume 7 Issue 10
This issue explores hematologic conditions in athletes, blue top tube shortages, and more.
Investigating the Combination of Ivosidenib Plus Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies
In a small study of patients with IDH1-mutated myeloid malignancies, treatment with ivosidenib plus venetoclax, with or without azacitidine, had an acceptable safety profile and led to high...
Current Issue
August 2021 Volume 7 Issue 10
This issue explores hematologic conditions in athletes, blue top tube shortages, and more.